AVTX Avalo Therapeutics, Inc. Common Stock
XNAS
6.77
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
AVTX
$6.77
—
Key stats
$6.77
Pre-market
$6.81
+0.59%
- 52-Week Range
- $6.53 – $24.27
- YTD
- -60.22%
- IV Rank (30D)
- 14.35
- Straddle Price
- $1.28
- P/C Vol Ratio
- 1.45
- Market Cap
- $0.4B
- Open
- $6.82
- Day Range
- $6.56 – $7.13
- Volume
- 2,370,681
- Prev Close
- $6.93
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 0.87 |
| Cost of Equity (CAPM) | 9.31% (VRP-adj) |
| WACC | 9.42% |
| Volatility Risk Premium | +117.9pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -22.4% |
| Book / Price | 290.9% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -115745.8% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $15.80 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $12.37 |
| Bollinger Width / SMA20 | 670.3% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $0B |
Peers used for multiples: DYN, IMNM, PCVX, UNH
(filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$27.28
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $77.31 | 19% | median 3.9× · 4 peers |
| Peer P/S | n/a | 0% | |
| Market Anchor (SMA50) | $15.80 | 81% | stability 85% (BB-width) |
| Options Expected (B-L 30d) | $6.64 | 0% | 6 strikes · skew +0.24 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.4B
- Employees
- 33
- List Date
- 2015-11-13
- CIK
- 0001534120
- Next Earnings
- 2026-11-05 (After-Close)
- EPS Forecast
- ($0.63) (5 est.)
- Headquarters
- Wayne, PA
- Homepage
- https://www.avalotx.com
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -45.70% | -21.26% | -46.61% | -0.12% | -11.22% | -24.98% |
| Feb | -- | -26.98% | -35.38% | -4.13% | -8.85% | 11.82% | -12.70% |
| Mar | -- | -11.46% | -35.19% | 392.08% | 19.55% | -16.96% | 69.60% |
| Apr | -- | -52.85% | 61.67% | -4.36% | -27.30% | -19.76% | -8.52% |
| May | -- | -14.28% | -6.82% | -26.97% | -20.63% | 16.34% | -10.47% |
| Jun | -- | 56.20% | -87.31% | 8.91% | 14.71% | 17.33% | 1.97% |
| Jul | -- | -42.31% | -43.02% | -9.75% | 63.02% | 4.67% | -5.48% |
| Aug | 7.64% | 31.94% | -48.72% | -36.65% | 17.74% | 7.15% | -3.48% |
| Sep | -32.72% | -29.36% | 32.06% | 20.10% | 40.91% | -19.10% | 1.98% |
| Oct | 4.00% | 84.62% | -7.52% | 44.69% | 39.12% | -54.72%* | 18.36% |
| Nov | -16.32% | -17.82% | -30.45% | -26.34% | 13.98% | -- | -15.39% |
| Dec | -9.09% | -11.42% | -41.76% | -24.57% | 8.22% | -- | -15.72% |
| Total | -42.70% | -83.98% | -99.09% | 5.76% | 234.36% | -62.90% | -8.09% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $12.37
SMA 50: $15.80
SMA 200: $16.23
Current: $6.77
EMA 12: $10.46
EMA 26: $12.59
MACD: -2.1343 | Signal: -0.5115
BEARISH
ADX (14): 51.64
STRONG TREND
+DI: 9.65
−DI: 49.32
Momentum Oscillators
RSI (14): 16.87
OVERSOLD
Stoch %K: 5.16
Stoch %D: 12.73
Williams %R: -96.78
Volume & Volatility
BB Upper: $17.50
BB Lower: $7.24
OVERSOLD
OBV: -12,368,894
Vol SMA 20: 2,602,974
Vol ROC: 371.08%
ATR: $1.17
True Range: $0.57
HV 20: 182.1%
HV 30: 152.1%
HV 60: 114.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 7/10)
Key Drivers and Primary Risks:
- High volatility and beta indicate increased risk
- Technical indicators point to a neutral trend, but recent price action suggests potential downtrend
- Recent news sentiment is generally positive, but options market signals indicate low expectations for near-term move
Investment Thesis: Avalo Therapeutics (AVTX) stock has been trending upward, driven by positive clinical trial data and strategic appointments. However, the high volatility and beta suggest that the stock may be due for a correction.
Recent News Sentiment Impact: The recent news headlines have generally been positive, with the company announcing successful clinical trials and strategic appointments. This sentiment is reflected in the options market, which suggests low expectations for near-term move.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): NEUTRAL
- Medium-term (1-3 months): BEARISH (based on recent price action and technical indicators)
- Long-term (3-12 months): BULLISH (based on positive clinical trial data and strategic appointments)
Support/Resistance Levels:
- SMA 20: $17.12 (support)
- EMA 26: $16.82 (support)
- Upper Bollinger Band: $23.21 (resistance)
Momentum Signals:
- RSI interpretation: NEUTRAL (47.87), oversold at 30 or below
- MACD signal: BULLISH, but MACD line is below the zero line, suggesting a potential downtrend
- Bollinger Bands position: SQUEEZE (price near upper band)
Volume Analysis:
- Volume SMA 20: 2817504.25 (support)
- On-Balance Volume (OBV): 32114414.42 (neutral)
- Volume Rate of Change: -26.02% (indicating a potential downtrend)
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines have been positive, with the company announcing successful clinical trials and strategic appointments.
Sentiment Assessment: The overall sentiment is POSITIVE, with four out of five recent news articles having a positive tone.
Catalyst Identification: There are no upcoming catalysts or earnings releases that could significantly impact the stock price in the near term.
Market Narrative: The technical signals suggest a potential downtrend, which is not aligned with the positive sentiment from recent news headlines.
Risk & Volatility Assessment
Beta Interpretation: High beta (1.68) indicates increased risk relative to the market.
Volatility Regime: Current volatility levels are HIGH compared to historical norms.
Options Market Signals: IV rank is LOW (10.3%), indicating low expectations for near-term move. The put/call volume ratio is NEUTRAL (0.81), suggesting that traders are not overly bearish or bullish on the stock.
Downside Protection: Support levels at SMA 20 and EMA 26 could provide some downside protection if the stock corrects.
Market Context & Positioning
Sector Performance: AVTX has been outperforming its sector peers in recent weeks, but this trend may be reversing.
Institutional Activity: There is no significant institutional activity to suggest that institutions are buying or selling the stock.
Correlation Analysis: The stock has a low correlation (0.22) with the overall market, indicating that it may not be closely tied to broader market trends.
Relative Valuation: The stock is trading near its 50-day moving average and above its 200-day moving average, suggesting that it may be slightly overvalued relative to its recent price action.
Key Levels & Action Items
Critical Price Levels:
- SMA 20: $17.12 (support)
- EMA 26: $16.82 (support)
Breakout/Breakdown Levels:
- Upper Bollinger Band: $23.21 (resistance)
- Lower Bollinger Band: $11.03 (support)
Time-Sensitive Catalysts: There are no upcoming catalysts or earnings releases that could significantly impact the stock price in the near term.
Risk Management: A stop-loss level at SMA 20 ($17.12) could help manage risk if the stock corrects. Position sizing should be cautious given the high volatility and beta.
Generated
News
All AVTX news →
Earnings History
6 of 6 under expected move
Avg Expected Move
42.82%
Avg Actual Move
4.78%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2025-05-12 | After-Close | 126.25% | 8.00% | 0.06x | Within |
| 2025-08-07 | After-Close | 53.89% | 6.95% | 0.13x | Within |
| 2025-11-06 | After-Close | 22.37% | 2.40% | 0.11x | Within |
| 2026-01-12 | After-Close | 19.20% | 3.18% | 0.17x | Within |
| 2026-05-11 | Pre-Market | 11.82% | 6.12% | 0.52x | Within |
| 2026-08-06 | After-Close | 23.40% | 2.03% | 0.09x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
AVTX Options Activity & IV Rank
AVTX IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 76.8%
7-DTE IV: —
Expected Move: $1.28
7-DTE Move: $1.28
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 67
Put Volume: 97
P/C Volume: 1.448
BEARISH
Call OI: 10,116
Put OI: 793
P/C OI: 0.078
Total OI: 10,909
ATM Options Pricing
ATM Call: $0.17
ATM Put: $1.10
Call %: 2.6%
Put %: 16.2%
Chain Summary
Chain Volume: 3,462
Chain OI: 24,242
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 62nd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
62%
vs own history
GEX tilt
+0.63
OI-weighted, today
Vanna tilt
+0.64
δ-sensitivity to IV
Charm tilt
-0.64
δ-decay vs time
Vanna tilt +0.64: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.64: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 5 ATM contracts, 12k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 92.0% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)14.3LowOct 26
Straddle Price (30 DTE)$1.28Oct 26
Beta Analysis
Risk Metrics
Beta: 1.3351
Alpha: -72.03%
Correlation: 0.1912
R-Squared: 3.7%
Stock Volatility: 89.0%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own AVTX
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Point72 Hedge fund Steve Cohen | $44.1M | #358 of 1945 | +160.6% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $6.6M | #1294 of 3138 | +197.4% | 13F | |
| Citadel Hedge fund Ken Griffin | $6.0M | #1955 of 6285 | +67.2% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
AVTX Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 22,778,562 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
6 filers$9.71M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $4.47M | 46.03% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $2.08M | 21.43% | 2026-06-30 |
| 3 | LMR Partners LLP | $1.74M | 17.91% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $1.07M | 11.00% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $341.88K | 3.52% | 2026-06-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $11.09K | 0.11% | 2026-06-30 |
7 filers$7.97M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Caption Management, LLC | $6.37M | 79.98% | 2026-06-30 |
| 2 | LMR Partners LLP | $554.40K | 6.96% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $304.92K | 3.83% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $255.02K | 3.20% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $232.85K | 2.92% | 2026-06-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $194.04K | 2.44% | 2026-06-30 |
| 7 | JPMorgan Chase & Co Custodian | $54.01K | 0.68% | 2026-06-30 |
AVTX Insider Trading (Form 4)
Latest: 2026-10-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Rita Jain | Director | Grant (A) | +1,322 opt | — | EDGAR | |
| 2026-10-02 | Ron M Philip | Director | Grant (A) | +1,109 opt | — | EDGAR | |
| 2026-10-02 | Kevin Robert Lind | Director | Grant (A) | +1,352 opt | — | EDGAR | |
| 2026-09-18 | Christopher Ryan Sullivan | Chief Financial Officer | Mixed | — | $13.11 | -$80.0K | EDGAR |
| 2026-09-11 | Christopher Ryan Sullivan | Chief Financial Officer | Mixed | — | $12.83 | -$97.6K | EDGAR |
| 2026-09-01 | Mittie Doyle | Chief Medical Officer | Mixed | — | $14.02 | -$8.1K | EDGAR |
| 2026-08-19 | Mittie Doyle | Chief Medical Officer | Mixed | — | $16.32 | -$7.3K | EDGAR |
| 2026-08-19 | Christopher Ryan Sullivan | Chief Financial Officer | Mixed | −873 | $14.94 | -$740.5K | EDGAR |
| 2026-08-12 | Mittie Doyle | Chief Medical Officer | Mixed | — | $14.02 | -$8.1K | EDGAR |
| 2026-08-12 | Jennifer Riley | Chief Strategy Officer | Sell (S) | −2,655 | $19.59 | -$52.0K | EDGAR |
| 2026-07-29 | Mittie Doyle | Chief Medical Officer | Mixed | — | $16.32 | -$7.3K | EDGAR |
| 2026-07-02 | Kevin Robert Lind | Director | Grant (A) | +1,105 opt | — | EDGAR | |
| 2026-07-02 | Rita Jain | Director | Grant (A) | +1,080 opt | — | EDGAR | |
| 2026-07-02 | Mittie Doyle | Chief Medical Officer | Mixed | — | $15.44 | -$42.4K | EDGAR |
| 2026-07-02 | Ron M Philip | Director | Grant (A) | +69 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
AVTX Insider Holdings
11 insiders · @ $6.77
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Garry Arthur Neil | Chief Executive Officer | 190,314 | $1.29M | $29.6K | 12 | 2026-05-26 |
| 2 | Mittie Doyle | Chief Medical Officer | 52,455 | $355.1K | -$2.98M | 18 | 2026-09-01 |
| 3 | Christopher Ryan Sullivan | Chief Financial Officer | 52,294 | $354.0K | -$3.72M | 20 | 2026-09-18 |
| 4 | Jennifer Riley | Chief Strategy Officer | 37,041 | $250.8K | -$52.0K | 6 | 2026-08-12 |
| 5 | Paul Varki | Chief Legal Officer | 32,576 | $220.5K | -$1.51M | 7 | 2026-06-12 |
| 6 | Jonathan Goldman | Director | 8,200 | $55.5K | -$162.9K | 4 | 2025-11-17 |
| 7 | June Sherie Almenoff | Director | 4,167 | $28.2K | $12.7K | 14 | 2025-06-18 |
| 8 | Gilla Kaplan | Director | 3,167 | $21.4K | $0 | 11 | 2026-06-04 |
| 9 | Aaron Kantoff | Director | 3,167 | $21.4K | $0 | 4 | 2026-06-04 |
| 10 | Samantha Truex | Director | 3,167 | $21.4K | $0 | 4 | 2026-06-04 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
AVTX Board & Officers
As of SEC filings through Oct 2, 2026Directors 8
- Gilla Kaplan · since Oct 8, 2020
- Garry Arthur Neil · listed since Oct 2022
- Aaron Kantoff · since Mar 28, 2024
- Samantha Truex · since Mar 28, 2024
- Michael Thomas Heffernan · since Mar 25, 2025
- Rita Jain · since Jun 17, 2025
- Kevin Robert Lind · since Oct 1, 2025
- Ron M Philip · since Jun 23, 2026
Officers 6
- Garry Arthur Neil · Chief Executive Officer · listed since Apr 2025
- Christopher Ryan Sullivan · Chief Financial Officer · listed since Mar 2022
- Paul Varki · Chief Legal Officer · since Jun 24, 2024
- Mittie Doyle · Chief Medical Officer · since Jul 15, 2024
- Jennifer Riley · Chief Strategy Officer · since Jan 1, 2025
- Taylor Boyd · Chief Business Officer · since Oct 1, 2025
Changes in the last 10 years (88)
| Jun 23, 2026 | Ron M Philip became a director |
| Mar 23, 2026 | The company announced the departure of Mitchell Chan from the board in an SEC filing |
| Mar 23, 2026 | The company announced the departure of Jonathan Goldman from the board in an SEC filing |
| Oct 1, 2025 | Taylor Boyd became Chief Business Officer |
| Oct 1, 2025 | Kevin Robert Lind became a director |
| Sep 16, 2025 | The company announced the departure of June Sherie Almenoff from the board in an SEC filing |
| Jun 17, 2025 | Rita Jain became a director |
| Apr 1, 2025 | Garry Arthur Neil listed as Chief Executive Officer (previously CEO and Chairman of the Board) in SEC filings |
| Mar 25, 2025 | Michael Thomas Heffernan became a director |
| Jan 1, 2025 | Jennifer Riley became Chief Strategy Officer |
| Jul 15, 2024 | Mittie Doyle became Chief Medical Officer |
| Jun 24, 2024 | Paul Varki became Chief Legal Officer |
| Mar 28, 2024 | Samantha Truex became a director |
| Mar 28, 2024 | Aaron Kantoff became a director |
| Mar 27, 2024 | Jonathan Goldman became a director |
| Jun 27, 2023 | Caissa Capital Management ltd. reported in an SEC filing no longer being a 10% owner |
| Apr 11, 2023 | Caissa Capital Management ltd. first on file as a 10% owner |
| Feb 9, 2023 | Armistice Capital, LLC no longer listed as a director in SEC filings |
| Feb 9, 2023 | Armistice Capital Master Fund Ltd. no longer listed as a director in SEC filings |
| Oct 7, 2022 | Garry Arthur Neil listed as CEO and Chairman of the Board (previously Chief Scientific Officer) in SEC filings |
| Oct 7, 2022 | Garry Arthur Neil first listed as a director in an SEC filing |
| Aug 8, 2022 | The company announced the departure of Steven Boyd from the board in an SEC filing |
| Aug 8, 2022 | The company announced the departure of Steven Boyd from the board in an SEC filing |
| Aug 8, 2022 | The company announced the departure of Illya Keith Maher from the board in an SEC filing |
| Mar 10, 2022 | Christopher Ryan Sullivan listed as Chief Financial Officer (previously Interim CFO) in SEC filings |
| Feb 14, 2022 | The company announced the departure of Michael F Cola from the board in an SEC filing |
| Feb 2, 2022 | The company announced the departure of H Jeffrey Wilkins as Chief Medical Officer in an SEC filing |
| Jan 3, 2022 | Stephen Smolinski became Chief Commercial Officer |
| Dec 1, 2021 | Phil Gutry left the board, per their own SEC filing |
| Dec 1, 2021 | Mitchell Chan became a director |
| Nov 10, 2021 | Suzanne Louise Bruhn left the board, per their own SEC filing |
| Nov 10, 2021 | June Sherie Almenoff became a director |
| Oct 15, 2021 | Illya Keith Maher became a director |
| Jun 14, 2021 | Schond L. Greenway listed as CFO (previously CFO & Treasurer) in SEC filings |
| Mar 8, 2021 | H Jeffrey Wilkins became Chief Medical Officer |
| Mar 1, 2021 | Schond L. Greenway became CFO & Treasurer |
| Jan 12, 2021 | Armistice Capital Master Fund Ltd. first listed as a director in an SEC filing |
| Nov 25, 2020 | Armistice Capital Master Fund Ltd. no longer listed as a director in SEC filings |
| Oct 8, 2020 | Gilla Kaplan became a director |
| Sep 9, 2020 | Armistice Capital Master Fund Ltd. first listed as a director in an SEC filing |
| Jun 11, 2020 | Joseph M Miller no longer listed as Chief Financial Officer in SEC filings |
| Jun 11, 2020 | Joseph M Miller first listed as a director in an SEC filing |
| Jun 11, 2020 | Garry Arthur Neil listed as Chief Scientific Officer (previously Chief Medical Officer) in SEC filings |
| Apr 24, 2020 | Suzanne Louise Bruhn became a director |
| Apr 24, 2020 | Christopher Ryan Sullivan became Interim CFO |
| Apr 17, 2020 | Pericles Calias reported in an SEC filing no longer being Chief Scientific Officer |
| Feb 3, 2020 | Sol J Barer became a director |
| Feb 3, 2020 | Michael F Cola became a director |
| Feb 3, 2020 | Michael F Cola became Chief Executive Officer |
| Feb 3, 2020 | Garry Arthur Neil became Chief Medical Officer |
| Dec 11, 2019 | James Archie Harrell Jr listed as Chief Commercial Officer (previously Exec. VP, Mktg & External Comm) in SEC filings |
| Jun 11, 2019 | Keith Schmidt became a director |
| May 29, 2019 | Peter Greenleaf no longer listed as Chief Executive Officer in SEC filings |
| May 16, 2019 | Simon Pedder listed as Executive Chairman of the Bd (previously Executive Chairman of Board) in SEC filings |
| Apr 17, 2019 | Simon Pedder first listed as Executive Chairman of Board in an SEC filing |
| Oct 18, 2018 | Robert Moscato Jr. reported in an SEC filing no longer being a director |
| Oct 18, 2018 | Robert Moscato Jr. reported in an SEC filing no longer being a 10% owner |
| Oct 18, 2018 | Robert Moscato Jr. reported in an SEC filing no longer being President and COO |
| Oct 18, 2018 | Robert Moscato Jr. first listed as a 10% owner in an SEC filing |
| Oct 18, 2018 | Randal Jones reported in an SEC filing no longer being a director |
| Oct 18, 2018 | Randal Jones reported in an SEC filing no longer being a 10% owner |
| Oct 18, 2018 | Randal Jones first listed as a 10% owner in an SEC filing |
| Oct 18, 2018 | LRS International, LLC reported in an SEC filing no longer being a 10% owner |
| Oct 18, 2018 | Fremantle, LLC reported in an SEC filing no longer being a 10% owner |
| Sep 25, 2018 | Patrick J Crutcher became VP, Business Development |
| Jul 18, 2018 | Armistice Capital Master Fund Ltd. no longer listed as a director in SEC filings |
| Jul 16, 2018 | Pericles Calias became Chief Scientific Officer |
| Jul 12, 2018 | Joseph M Miller became Chief Financial Officer |
| May 17, 2018 | Uli Hacksell no longer listed as President and CEO in SEC filings |
| May 17, 2018 | Armistice Capital Master Fund Ltd. first listed as a director in an SEC filing |
| May 15, 2018 | LRS International, LLC became a 10% owner |
| May 15, 2018 | Fremantle, LLC became a 10% owner |
| May 7, 2018 | James Archie Harrell Jr became Exec. VP, Mktg & External Comm |
| Apr 6, 2018 | Simon Pedder became a director |
| Mar 29, 2018 | Peter Greenleaf first listed as Chief Executive Officer in an SEC filing |
| Jan 22, 2018 | Matthew V Phillips became Chief Commercial Officer |
| Nov 17, 2017 | Robert Moscato Jr. became a director |
| Nov 17, 2017 | Robert Moscato Jr. became President and COO |
| Nov 17, 2017 | Randal Jones became a director |
| Sep 20, 2017 | Steven Boyd first listed as a director in an SEC filing |
| Jul 5, 2017 | Armistice Capital Master Fund Ltd. no longer listed as a director in SEC filings |
| May 23, 2017 | Steven Boyd first listed as a director in an SEC filing |
| May 23, 2017 | Armistice Capital, LLC first listed as a director in an SEC filing |
| May 23, 2017 | Armistice Capital Master Fund Ltd. first listed as a director in an SEC filing |
| May 12, 2017 | Peter Greenleaf became a director |
| Apr 27, 2017 | Steven Boyd became a 10% owner |
| Apr 27, 2017 | Armistice Capital, LLC became a 10% owner |
| Apr 27, 2017 | Armistice Capital Master Fund Ltd. became a 10% owner |
Not reported recently (21)
- Magnus Persson · Last reported as a director in an SEC filing dated Dec 21, 2023
- Armistice Capital, LLC · Last reported as a 10% owner in an SEC filing dated Jun 28, 2023
- Armistice Capital Master Fund Ltd. · Last reported as a 10% owner in an SEC filing dated Jun 28, 2023
- Steven Boyd · Last reported as a 10% owner in an SEC filing dated Jun 28, 2023
- Joseph M Miller · Last reported as a director in an SEC filing dated Apr 4, 2022
- Stephen Smolinski · Last reported as Chief Commercial Officer in an SEC filing dated Jan 6, 2022
- James Archie Harrell Jr · Last reported as Chief Commercial Officer in an SEC filing dated Dec 14, 2021
- Schond L. Greenway · Last reported as CFO in an SEC filing dated Dec 14, 2021
- Michael F Cola · Last reported as Chief Executive Officer in an SEC filing dated Oct 4, 2021
- Sol J Barer · Last reported as a director in an SEC filing dated Jun 17, 2021
- Simon Pedder · Last reported as a director in an SEC filing dated Apr 13, 2020
- Uli Hacksell · Last reported as a director in an SEC filing dated Apr 2, 2020
- Matthew V Phillips · Last reported as Chief Commercial Officer in an SEC filing dated Oct 21, 2019
- Peter Greenleaf · Last reported as a director in an SEC filing dated Oct 3, 2019
- Keith Schmidt · Last reported as a director in an SEC filing dated Oct 3, 2019
- Patrick J Crutcher · Last reported as VP, Business Development in an SEC filing dated Apr 2, 2019
- Isaac Blech · Last reported as a director in an SEC filing dated Jan 2, 2019
- Eugene A Bauer · Last reported as a director in an SEC filing dated Apr 4, 2018
- Mariam E Morris · Last reported as Chief Financial Officer in an SEC filing dated Jan 24, 2018
- John Joseph Kaiser · Last reported as Chief Business Officer in an SEC filing dated Aug 22, 2017
- Thomas H Aasen · Last reported as a director in an SEC filing dated Jul 31, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
AVTX Proposed Insider Sales (Form 144)
Latest: 2026-08-18
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
6 filings
· $2.2M notice value
· 3 unique filers
· 50% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
CHRISTOPHER RYAN SULLIVAN (3, $2.1M) · MITTIE DOYLE (2, $111K) · JENNIFER RILEY (1, $52K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-18 | CHRISTOPHER RYAN SULLIVAN | Officer | 31,031 | $622.2K | 2026-08-18 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-17 | MITTIE DOYLE | Officer | 5,037 | $98.7K | 2026-08-17 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-17 | CHRISTOPHER RYAN SULLIVAN | Officer | 70,709 | $1.39M | 2026-08-17 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-17 | CHRISTOPHER RYAN SULLIVAN | Officer | 3,749 | $74.8K | 2026-08-17 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-11 | JENNIFER RILEY | Officer | 2,655 | $52.0K | 2026-08-11 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-10 | MITTIE DOYLE | Officer | 679 | $12.4K | 2026-08-10 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-02 | JONATHAN GOLDMAN | Director | 42,833 | $616.2K | 2026-06-02 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-05-07 | CHRISTOPHER SULLIVAN | Officer | 18,606 | $405.8K | 2026-05-07 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-05-06 | MITTIE DOYLE | Officer | 54,508 | $886.3K | 2026-05-06 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-05-06 | CHRISTOPHER SULLIVAN | Officer | 47,000 | $764.2K | 2026-05-06 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
37 ETFs hold AVTX
25 shown · $67.87M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $25.7M | — | 2026-09-30 |
| 2 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.10% | $10.8M | $10.4B | 2026-10-23 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $8.9M | $74.6B | 2026-10-23 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $8.1M | — | 2026-09-30 |
| 5 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.03% | $4.6M | — | 2026-09-30 |
| 6 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.01% | $1.7M | $13.7B | 2026-10-23 |
| 7 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.02% | $1.6M | $6.6B | 2026-10-23 |
| 8 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.01% | $1.6M | $13.9B | 2026-10-23 |
| 9 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.09% | $1.1M | $1.2B | 2026-10-23 |
| 10 | TMSL T. Rowe Price Small-Mid Cap ETF | Nport | 0.02% | $594,723 | — | 2026-06-30 |
| 11 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $558,031 | $96.5B | 2026-10-23 |
| 12 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.03% | $431,585 | — | 2026-09-30 |
| 13 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.07% | $421,593 | — | 2026-10-26 |
| 14 | BBC Virtus Biotech Clinical Trials Etf | Nport | 0.83% | $384,308 | — | 2026-07-31 |
| 15 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.03% | $356,729 | — | 2026-09-30 |
| 16 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.01% | $217,588 | $3.2B | 2026-10-23 |
| 17 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.00% | $195,149 | $10.7B | 2026-10-23 |
| 18 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $166,413 | — | 2026-10-26 |
| 19 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.00% | $165,987 | $3.8B | 2026-10-23 |
| 20 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.01% | $85,821 | $1.0B | 2026-10-23 |
| 21 | TMED T. Rowe Price Health Care ETF | Nport | 0.34% | $79,224 | — | 2026-06-30 |
| 22 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $78,177 | $20.4B | 2026-10-23 |
| 23 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $71,913 | — | 2026-09-30 |
| 24 | WSML iShares MSCI World Small-Cap ETF | iShares (BlackRock) | 0.00% | $26,022 | $657.8M | 2026-10-23 |
| 25 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.01% | $19,762 | — | 2026-10-26 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-4.37
TTM Revenue
$59.00K
TTM Net Income
$-100.33M
TTM Op. Cash Flow
$-68.29M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-36.36M | $-0.83 | $-19.99M |
| Q1 '26 | 2026-03-31 | — | $-19.63M | $-0.98 | $-17.69M |
| Q4 '25 | 2025-12-31 | $59.00K | $-13.72M | $-0.37 | $-14.25M |
| Q3 '25 | 2025-09-30 | — | $-30.62M | $-2.19 | $-16.36M |
| Q2 '25 | 2025-06-30 | — | $-20.77M | $-1.92 | $-11.39M |
| Q1 '25 | 2025-03-31 | — | $-13.15M | $-1.25 | $-9.46M |
| Q4 '24 | 2024-12-31 | $192.00K | $-35.16M | $1.72 | $-15.04M |
| Q3 '24 | 2024-09-30 | $249.00K | $5.46M | $-2.83 | $-11.53M |
| Q2 '24 | 2024-06-30 | — | $4.35M | $-14.07 | $-16.28M |
| Q1 '24 | 2024-03-31 | — | $-121.29M | $-141.14 | $-6.20M |
| Q4 '23 | 2023-12-31 | $571.00K | $-8.17M | $117.47 | $-2.77M |
| Q3 '23 | 2023-09-30 | $236.00K | $-5.23M | $-26.83 | $-6.84M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.34
P/S
2613.74
EV/EBITDA
—
EV/Sales
1166.59
ROE
-22.4%
ROA
-20.4%
Div Yield
0.00%
FCF Yield
-44.28%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$154.21M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
11.41M
SI % of Float
23.47%
Days to Cover
8.80
Short Vol Ratio
32.3%
Free Float
48.59M
Float %
90.6%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-09-22